The Human Acellular Vessel (HAV) as a vascular conduit for infrainguinal arterial bypass

Armin Farazdaghi; Indrani Sen; Peter B. Anderson; Fahad Shuja; Todd E. Rasmussen

doi:10.1016/j.jvscit.2023.101123

The Human Acellular Vessel (HAV) as a vascular conduit for infrainguinal arterial bypass

Armin Farazdaghi, Indrani Sen, Peter B. Anderson, Fahad Shuja, Todd E. Rasmussen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Autologous vein is the optimal conduit for peripheral arterial bypass surgery, a standard recently highlighted by findings from the BEST-CLI trial. The Human Acellular Vessel is a novel biologic conduit produced using regenerative medicine technologies with structural and mechanical properties like a human blood vessel. Not yet approved by the United States Food and Drug Administration, the Human Acellular Vessel is being studied as an alternative bypass conduit in patients with peripheral arterial disease, vascular injury, and those in need of arteriovenous access for hemodialysis. This report describes and illustrates the technical aspects of intraoperative handling specific to the use of this new and innovative technology.

Original language	English
Article number	101123
Journal	Journal of Vascular Surgery Cases and Innovative Techniques
Volume	9
Issue number	3
DOIs	https://doi.org/10.1016/j.jvscit.2023.101123
State	Published - Sep 2023
Externally published	Yes

Keywords

Arterial reconstruction
Bioengineered vessel
Chronic limb-threatening ischemia
Critical limb-threatening ischemia
HAV
Human acellular vessel
Peripheral arterial disease
Regenerative medicine

Access to Document

10.1016/j.jvscit.2023.101123

Cite this

@article{950759f6584c45d6bc03dc244defe1ea,

title = "The Human Acellular Vessel (HAV) as a vascular conduit for infrainguinal arterial bypass",

abstract = "Autologous vein is the optimal conduit for peripheral arterial bypass surgery, a standard recently highlighted by findings from the BEST-CLI trial. The Human Acellular Vessel is a novel biologic conduit produced using regenerative medicine technologies with structural and mechanical properties like a human blood vessel. Not yet approved by the United States Food and Drug Administration, the Human Acellular Vessel is being studied as an alternative bypass conduit in patients with peripheral arterial disease, vascular injury, and those in need of arteriovenous access for hemodialysis. This report describes and illustrates the technical aspects of intraoperative handling specific to the use of this new and innovative technology.",

keywords = "Arterial reconstruction, Bioengineered vessel, Chronic limb-threatening ischemia, Critical limb-threatening ischemia, HAV, Human acellular vessel, Peripheral arterial disease, Regenerative medicine",

author = "Armin Farazdaghi and Indrani Sen and Anderson, {Peter B.} and Fahad Shuja and Rasmussen, {Todd E.}",

note = "Publisher Copyright: {\textcopyright} 2023",

year = "2023",

month = sep,

doi = "10.1016/j.jvscit.2023.101123",

language = "English",

volume = "9",

journal = "Journal of Vascular Surgery Cases and Innovative Techniques",

issn = "2468-4287",

number = "3",

}

TY - JOUR

T1 - The Human Acellular Vessel (HAV) as a vascular conduit for infrainguinal arterial bypass

AU - Farazdaghi, Armin

AU - Sen, Indrani

AU - Anderson, Peter B.

AU - Shuja, Fahad

AU - Rasmussen, Todd E.

PY - 2023/9

Y1 - 2023/9

N2 - Autologous vein is the optimal conduit for peripheral arterial bypass surgery, a standard recently highlighted by findings from the BEST-CLI trial. The Human Acellular Vessel is a novel biologic conduit produced using regenerative medicine technologies with structural and mechanical properties like a human blood vessel. Not yet approved by the United States Food and Drug Administration, the Human Acellular Vessel is being studied as an alternative bypass conduit in patients with peripheral arterial disease, vascular injury, and those in need of arteriovenous access for hemodialysis. This report describes and illustrates the technical aspects of intraoperative handling specific to the use of this new and innovative technology.

AB - Autologous vein is the optimal conduit for peripheral arterial bypass surgery, a standard recently highlighted by findings from the BEST-CLI trial. The Human Acellular Vessel is a novel biologic conduit produced using regenerative medicine technologies with structural and mechanical properties like a human blood vessel. Not yet approved by the United States Food and Drug Administration, the Human Acellular Vessel is being studied as an alternative bypass conduit in patients with peripheral arterial disease, vascular injury, and those in need of arteriovenous access for hemodialysis. This report describes and illustrates the technical aspects of intraoperative handling specific to the use of this new and innovative technology.

KW - Arterial reconstruction

KW - Bioengineered vessel

KW - Chronic limb-threatening ischemia

KW - Critical limb-threatening ischemia

KW - HAV

KW - Human acellular vessel

KW - Peripheral arterial disease

KW - Regenerative medicine

UR - http://www.scopus.com/inward/record.url?scp=85169844325&partnerID=8YFLogxK

U2 - 10.1016/j.jvscit.2023.101123

DO - 10.1016/j.jvscit.2023.101123

M3 - Article

AN - SCOPUS:85169844325

SN - 2468-4287

VL - 9

JO - Journal of Vascular Surgery Cases and Innovative Techniques

JF - Journal of Vascular Surgery Cases and Innovative Techniques

IS - 3

M1 - 101123

ER -

The Human Acellular Vessel (HAV) as a vascular conduit for infrainguinal arterial bypass

Abstract

Keywords

Access to Document

Fingerprint

Cite this